GLP-1 Check — India's GLP-1 Information & Self-Assessment Tool
All comparisons

Noveltreat vs Sematrinity in India — Same Molecule, Different Indication

Last reviewed 12 May 2026 · India-specific clinical evidence

The short answer

Noveltreat and Sematrinity are both Sun Pharma's Indian generic semaglutide — pharmacologically identical. The difference is the DCGI label: Noveltreat is approved for obesity (chronic weight management), Sematrinity for type 2 diabetes. Price range is the same (₹750–2,000/month). Pick Noveltreat if your goal is weight management at BMI ≥27.5; pick Sematrinity if you have T2D needing add-on glycaemic control.

Not sure which one applies to you?

Take the 5-minute Indian-guideline eligibility check.

Take the free assessment →

Noveltreat vs Sematrinity — at a glance

AttributeNoveltreatSematrinity
Active ingredientSemaglutideSemaglutide
ManufacturerSun PharmaSun Pharma
Indication (India)Obesity / Chronic Weight ManagementType 2 Diabetes
DCGI approvalDecember 2025December 2025
Pen formatConcealed-needle prefilled penMulti-dose pen
FrequencyOnce weeklyOnce weekly
Approx. monthly price (India, 2026)₹750–2,000₹750–2,000
Target patientBMI ≥27.5, or ≥25 with comorbiditiesT2D, often add-on to metformin
Pen-design rationaleConcealed needle reduces injection anxietyMulti-dose simplifies T2D titration
Prescription requiredYes (Schedule H)Yes (Schedule H)
Innovator equivalentWegovy (Novo Nordisk)Ozempic (Novo Nordisk)

Efficacy — what the trials show

Noveltreat

Same molecule as Wegovy, so the same STEP trial evidence applies — mean ~14.9% body weight loss at 2.4 mg over 68 weeks (STEP-1, NEJM 2021). Sun Pharma's India-specific Phase III data supports bioequivalence and Indian-population efficacy. Patients reach 2.4 mg target dose through the same 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg titration schedule used for innovator semaglutide.

Sematrinity

Same molecule as Ozempic — efficacy mirrors the SUSTAIN trial series. Mean HbA1c reduction of 1.4–1.8% at 1 mg dose, ~10% weight reduction at 2 mg in T2D patients on metformin background. Sun Pharma's Indian Phase III trial supports Indian-population glycaemic outcomes comparable to international SUSTAIN data.

Cost in India (2026)

Noveltreat

Noveltreat: ₹750–2,000/month. Roughly 5-8× cheaper than Wegovy (₹5,660–16,400/month) for the same active molecule. Pen format adds modest cost vs vial; the concealed needle is targeted at first-time semaglutide users who fear injections.

Sematrinity

Sematrinity: ₹750–2,000/month — same range as Noveltreat. Roughly 3-4× cheaper than Ozempic (₹5,660–9,100/month). Multi-dose pen design reduces per-dose cost during T2D dose-escalation.

Side effects

Noveltreat

Identical side-effect profile to Wegovy. Most common (>10%): nausea (44% in STEP-1), diarrhea (32%), vomiting (25%), peaking during titration weeks 1-8. Indian patients on rich/oily diets during titration report higher GI intolerance — nutritionist co-management is recommended.

Sematrinity

Identical side-effect profile to Ozempic. Most common (>10%): nausea, diarrhea, vomiting, constipation, abdominal pain — mostly transient during titration. T2D-specific considerations: monitor for hypoglycaemia if used alongside insulin or sulfonylureas (dose adjustments often needed).

Which one should you consider?

Pick Noveltreat if

  • ✓Your primary goal is weight management, not glucose control
  • ✓You meet Indian BMI criteria (≥27.5 or ≥25 with comorbidities)
  • ✓Injection anxiety is a barrier — the concealed-needle pen helps
  • ✓You want generic-price semaglutide for the obesity indication

Pick Sematrinity if

  • ✓You have type 2 diabetes
  • ✓You're on metformin and HbA1c isn't at target
  • ✓You want generic-price semaglutide with multi-dose pen flexibility
  • ✓Your endocrinologist is comfortable with the T2D Indian generic

Frequently asked questions

Is Noveltreat the same as Sematrinity?+
The active molecule is identical — both are Sun Pharma's Indian generic semaglutide. The DCGI label differs: Noveltreat is approved for obesity (chronic weight management), Sematrinity for type 2 diabetes. Sun Pharma is mirroring Novo Nordisk's Ozempic / Wegovy dual-brand strategy: same molecule, two indications, two brand names.
Why does Sun Pharma sell two brands of the same molecule?+
Because the indications and prescribing channels are distinct. Endocrinologists treating diabetes prescribe through one workflow (HbA1c-driven, RSSDI guideline framework). Obesity prescribers operate through a different channel (BMI-driven, often paired with bariatric or weight-management clinics). Two brand names let Sun Pharma's sales force address both audiences cleanly without label confusion.
Can I use Noveltreat off-label for diabetes (or Sematrinity for weight loss)?+
In India, off-label prescribing is at your physician's discretion. Many endocrinologists do prescribe Sematrinity for obesity-comorbid T2D patients (the obesity benefit is a known class effect). Off-label Noveltreat for diabetes is more uncommon since Sematrinity exists at the same price. The molecule does the same biological work either way — the labeling reflects the formal regulatory indication, not a pharmacological boundary.
Which is cheaper — Noveltreat or Sematrinity?+
Both are priced identically: ₹750–2,000/month depending on dose. Sun Pharma intentionally aligned prices — the brand differentiation is on labeling and pen design, not price. Either is 3-8× cheaper than the equivalent innovator brand (Wegovy or Ozempic).
Are Noveltreat and Sematrinity bioequivalent to Wegovy and Ozempic?+
Yes — DCGI-approved generic semaglutide products must demonstrate bioequivalence to the innovator. Sun Pharma's Indian Phase III trials support Indian-population safety and efficacy comparable to international STEP/SUSTAIN data. Clinical outcomes follow the molecule, not the brand.
Which is best for PCOS — Noveltreat or Sematrinity?+
Neither is directly approved for PCOS in India. For obesity-comorbid PCOS (BMI ≥27.5 or ≥25 with comorbidity), Noveltreat is the on-label choice. For T2D-comorbid PCOS, Sematrinity. Many endocrinology + gynaecology teams co-manage PCOS patients on either brand based on the dominant comorbidity.
Will GLP-1 Check's triage recommend Noveltreat vs Sematrinity?+
The 5-minute triage factors in your BMI, HbA1c, comorbidities, and goals to map your fit to an indication (obesity vs T2D). For patients with primary obesity, Noveltreat-class brands are matched; for T2D, Sematrinity-class brands. Final brand choice is made between you and your endocrinologist based on cost, pen preference, and clinical history.

Related comparisons

Ozempic vs Wegovy

Ozempic vs Wegovy in India — Which One Do You Actually Need?

Mounjaro vs Wegovy

Mounjaro vs Wegovy in India — Which Loses More Weight?

Semaglutide vs Tirzepatide

Semaglutide vs Tirzepatide in India — Class-Level Comparison

Find out which one fits your profile

The 5-minute Indian-guideline assessment uses your BMI, comorbidities, and lab values (optional) to recommend an evidence-based starting point.

Start the free assessment →

Information based on DCGI-approved labelling, peer-reviewed trials (STEP, SUSTAIN, SURMOUNT, SURPASS, SELECT), and ESI India clinical guidelines. Always consult a qualified medical practitioner before starting or switching therapy. Both molecules referenced here are Schedule H drugs in India.